Remove Antibody Remove Contract Manufacturing Remove Marketing Remove Sales
article thumbnail

Antibody Drug Conjugates Market Update: Ambrx and NovoCodex Collaborate

Roots Analysis

Ambrx and NovoCodex Biopharmaceuticals announced that they have formed a second collaboration to develop and commercialize Ambrx’s internally developed site-specific antibody drug conjugates. The antibody drug conjugates market is expected to grow at a CAGR of ~10% during the forecast period.

article thumbnail

Subcutaneous Medications and Drug Delivery Systems

Roots Analysis

In fact, the share of biologics in the overall pharmaceutical contract manufacturing market has increased from 16% in 2006 to over 25% in 2017. Having reported over 70% increase in revenues over the past 5-6 years, the market for biologically derived products is currently estimated to be worth more than USD 200 billion.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Boehringer Ingelheim and Twist Bioscience Enter Therapeutic Antibody Discovery Collaboration

The Pharma Data

Boehringer Ingelheim believes Twist’s ability to generate potent, diverse therapeutic antibodies by mining its comprehensive libraries, combined with our extensive capabilities and experience in drug discovery and development, will enable us to deliver breakthrough opportunities to patients,” said Clive R. About Twist Bioscience Corporation.

article thumbnail

Decline of novel drug approvals means less business for cutting-edge CMOs

Pharmaceutical Technology

This is mixed news for contract manufacturing organisations (CMOs), as large CMOs such as Thermo Fisher Scientific (Waltham, MA, US) and Catalent Inc (Somerset, NJ, US) are typically involved in the manufacture of the most innovative products. However, non-NME and biosimilar approvals increased in 2022.

Drugs 130
article thumbnail

First half of 2021: Boehringer Ingelheim makes fundamental progress in research and development

The Pharma Data

In July, Boehringer Ingelheim reported a breakthrough in the treatment of heart failure with empagliflozin (marketed as JARDIANCE ® ). In June, the European Commission granted marketing authorization for JARDIANCE ® as a treatment for adults with symptomatic chronic heart failure with reduced ejection fraction (HFrEF). billion EUR.

article thumbnail

Boehringer Ingelheim sees positive business momentum in 2020 despite impact of COVID-19

The Pharma Data

of net sales). Outlook 2021: slight year-on-year increase in net sales on a comparable basis. Other COVID-19 initiatives include the research and development of SARS-CoV-2 antibodies that can be combined with BI 767551, small molecules to inhibit its replication, and therapy development to prevent micro coagulation (blood clots).

Sales 52
article thumbnail

FDA rejects Provention’s type 1 diabetes drug teplizumab

pharmaphorum

The complete response letter (CRL) for teplizumab as a treatment to delay clinical type 1 diabetes in at-risk individuals reiterates the FDA’s concerns around the pharmacokinetics (PK) data for the antibody.

Drugs 98